IMMUNODIAGNOSTIC FOR MEASURING HUMAN CELL PROLIFERATION

Award Information

Agency: Department of Health and Human Services

Branch: N/A

Contract: N/A

Agency Tracking Number: 11125

Amount: $50,000.00

Phase: Phase I

Program: SBIR

Solicitation Topic Code: N/A

Solicitation Number: N/A

Timeline

Solicitation Year: N/A

Award Year: 1989

Award Start Date (Proposal Award Date): N/A

Award End Date (Contract End Date): N/A

Small Business Information

CBR LABORATORIES, INC.

800 Huntington Ave

Boston, MA 02115

United States

DUNS: N/A

HUBZone Owned: No

Woman Owned: No

Socially and Economically Disadvantaged: No

Principal Investigator

Phone: () -

Business Contact

Phone: () -

Research Institution

N/A

Abstract

THE EVALUATION OF TISSUES FOR THE PRESENCE OF CANCER CELLS IN ABNORMAL TISSUES IS AN IMPORTANT AND CRUCIAL STEP IN THE DIAGNOSIS, DISEASE MANAGEMENT, AND CONTROL OF CANCER. CBR LABORATORIES, INC., HAS GENERATED A MOUSE MONOCLONAL ANTIBODY THAT DETECTS A GLYCOLIPID ANTIGEN (PAA) ON PROLIFERATING T CELLS, B CELLS, AND TUMOR CELLS IN BOTH FROZEN AND PARAFFIN-FIXED TISSUES. IT IS HYPOTHESIZED THAT THE LEVEL OF BINDING OF THIS ANTIBODY TO A CELL REFLECTS ITSPROLIFERATION POTENTIAL. THIS CONCEPT WILL BE TESTED IN A SERIES OF EXPERIMENTS THAT INCLUDE IN SITU COMPARATIVE IMMUNOHISTOCHEMICAL STAINING OF PROLIFERATING CELLS IN LYMPHOMAS AND A VARIETY OF SOLID TUMORS WITH ANTI-PAA MONOCLONAL ANTIBODY THAT IS USED TO STAIN PROLIFERATING CELLS IN FROZEN SECTIONS OF NORMAL AND CANCER TISSUE. DIGITAL IMAGE ANALYSIS AND IMMUNOFLUORESCENCE STAINING WILL BE USED FOR THE IN SITU STUDIES. THE RESULTS OF THESE STUDIES WILL DETERMINE THE FEASIBILITY OF USING ANTI-PAA MONOCLONAL ANTIBODY AS AN IMMUNODIAGNOSTIC REAGENT FOR THE DETECTION OF PROLIFERATING CELLS IN TUMORS.

* Information listed above is at the time of submission. *

You are here

IMMUNODIAGNOSTIC FOR MEASURING HUMAN CELL PROLIFERATION